Genome-Wide Analysis Identifies BACH2 as Potential Fetal Hemoglobin Activation Target

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 30 Sept, 18:48 UTC

This pathway, which the authors dub the “BACH2-NRF2 axis,” is independent of the well-known BCL11A transcription regulator, the target of the approved cell therapy Casgevy for sickle cell disease (SCD). The post Genome-Wide Analysis Identifies BACH2 as Potential Fetal Hemoglobin Activation Target…

policyscience

Sources

• T2Genome-Wide Analysis Identifies BACH2 as Potential Fetal Hemoglobin Activation TargetFierce Biotech / Fierce Healthcare / MedCity / GEN30 Sept, 18:48